CT-0508 is under clinical development by CTx Operations and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase I drugs for Bile Duct Cancer (Cholangiocarcinoma) have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CT-0508’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CT-0508 overview
CT-0508 is under development for the treatment of HER2-positive solid tumors including ovarian cancer, breast cancer, peritoneal cancer, Cholangiocarcinoma, Salivary Carcinoma, gastric cancer and gastroesophageal junction cancer. It is developed based on the CARMA platform that combines chimeric antigen receptor targeting with macrophages to tackle solid tumors. The drug candidate is genetically engineered adenovirus (Ad5f35) -transduced anti-HER2 CAR. It is administered through intravenous and intraperitoneal route.
CTx Operations overview
CTx Operations, Inc (CTx Operations), formerly Carisma Therapeutics Inc, is a biotechnology service provider that discovers and develops macrophage-based immunotherapeutic for the treatment of cancer. The company product CAR-macrophage platform to provide human macrophages the capability to identify relevant targets to exterminate cancer cells in solid tumors. CTx Operations technology harnesses the latest developments in macrophage biology, chimeric antigen receptor engineering and adoptive cellular therapy to treat multiple diseases in humans. Its portfolio includes CT – 0508 (HER2), CT – 1119 (Mesothelin), CT – 0729 (PSMA) which treat mesothelin-positive solid tumors, prostate cancer, neurodegeneration, liver fibrosis and others. It is a subsidiary of Carisma Therapeutics Inc. CTx Operations is headquartered in Philadelphia, Pennsylvania, the US.
For a complete picture of CT-0508’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
